河马效应器YAP调节癌细胞对MAPK通路抑制剂的反应。
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.
作者信息
Lin Luping, Bivona Trever G
机构信息
Division of Hematology and Medical Oncology; University of California San Francisco; San Francisco, CA USA; Helen Diller Family Comprehensive Cancer Center; University of California San Francisco; San Francisco, CA USA.
出版信息
Mol Cell Oncol. 2015 Apr 27;3(1):e1021441. doi: 10.1080/23723556.2015.1021441. eCollection 2016 Jan.
Abstract
RAF- and MEK-targeted therapies are approved for patients with BRAF(V600E) melanoma and under investigation in a several other tumor types, but resistance remains a major challenge. We uncovered yes-associated protein 1 (YAP1) as a mechanism of resistance to RAF-MEK inhibition in BRAF- and RAS-mutant cancers, providing a rationale for co-targeting YAP and RAF-MEK to enhance patient outcomes.
摘要
针对BRAF（V600E）黑色素瘤患者，RAF和MEK靶向疗法已获批准，并且正在其他几种肿瘤类型中进行研究，但耐药性仍然是一个重大挑战。我们发现Yes相关蛋白1（YAP1）是BRAF和RAS突变癌症中对RAF-MEK抑制产生耐药性的一种机制，这为联合靶向YAP和RAF-MEK以改善患者预后提供了理论依据。
相似文献
1
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.河马效应器YAP调节癌细胞对MAPK通路抑制剂的反应。
Mol Cell Oncol. 2015 Apr 27;3(1):e1021441. doi: 10.1080/23723556.2015.1021441. eCollection 2016 Jan.
2
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.河马效应器YAP可促进对RAF和MEK靶向癌症疗法的抗性。
Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.
3
Yes-activated protein promotes primary resistance of V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors.Yes 激活蛋白促进 V600E 突变型转移性结直肠癌细胞对丝裂原活化蛋白激酶途径抑制剂的原发性耐药。
J Gastrointest Oncol. 2021 Jun;12(3):953-963. doi: 10.21037/jgo-21-258.
4
Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.Yap 调控特定谱系神经调节素 1 通路驱动的适应性耐药机制以抵抗 RAF 激酶抑制剂。
Mol Cancer. 2022 Dec 7;21(1):213. doi: 10.1186/s12943-022-01676-9.
5
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.针对人类癌症中致癌性 Raf 蛋白-丝氨酸/苏氨酸激酶。
Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15.
6
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.BRAF抑制剂治疗诱导产生的活性氧（ROS）重编程代谢过程，影响黑色素瘤细胞的生长。
Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y.
7
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.MAPK 信号的过度激活对 RAS/RAF 突变型黑色素瘤有害。
Mol Cancer Res. 2019 Jan;17(1):199-211. doi: 10.1158/1541-7786.MCR-18-0327. Epub 2018 Sep 10.
8
Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma.BRAF 突变型黑色素瘤中对丝裂原活化蛋白激酶途径抑制的耐药机制
Am Soc Clin Oncol Educ Book. 2012:680-4. doi: 10.14694/EdBook_AM.2012.32.189.
9
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.BRAF 突变型结直肠癌中通过 MAPK 通路改变对 RAF 抑制剂联合治疗产生临床获得性耐药
Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.
10
MEK and RAF inhibitors for BRAF-mutated cancers.MEK 和 RAF 抑制剂治疗 BRAF 突变型癌症。
Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11.
引用本文的文献
1
A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman.综述与观点论文：Ras 癌基因从主谋到小喽啰。
Cell Mol Life Sci. 2024 Oct 1;81(1):412. doi: 10.1007/s00018-024-05449-z.
2
Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma.在Hippo通路缺陷型间皮瘤中对TEAD棕榈酰化抑制剂进行比较评估和高通量药物组合分析
Pharmaceuticals (Basel). 2023 Nov 21;16(12):1635. doi: 10.3390/ph16121635.
3
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.靶向 RAS/RAF/MAPK 通路治疗癌症：从机制到临床研究。
Signal Transduct Target Ther. 2023 Dec 18;8(1):455. doi: 10.1038/s41392-023-01705-z.
4
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.CRISPR 筛选鉴定非小细胞肺癌中 KRASG12C 和 SHP2 抑制剂联合耐药的机制
Cancer Res. 2023 Dec 15;83(24):4130-4141. doi: 10.1158/0008-5472.CAN-23-1127.
5
Characterization of proteome-size scaling by integrative omics reveals mechanisms of proliferation control in cancer.综合组学对蛋白质组大小缩放的特征分析揭示了癌症增殖控制的机制。
Sci Adv. 2023 Jan 25;9(4):eadd0636. doi: 10.1126/sciadv.add0636.
6
Yes-activated protein promotes primary resistance of V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors.Yes 激活蛋白促进 V600E 突变型转移性结直肠癌细胞对丝裂原活化蛋白激酶途径抑制剂的原发性耐药。
J Gastrointest Oncol. 2021 Jun;12(3):953-963. doi: 10.21037/jgo-21-258.
7
Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.用维替泊芬靶向葡萄膜和结膜黑色素瘤的 YAP/TAZ 通路。
Invest Ophthalmol Vis Sci. 2021 Apr 1;62(4):3. doi: 10.1167/iovs.62.4.3.
8
The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review.河马通路在乳腺癌发生、预后及治疗中的作用：一项系统综述
Breast Care (Basel). 2021 Feb;16(1):6-15. doi: 10.1159/000507538. Epub 2020 May 12.
9
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.黑色素瘤中获得性BRAF抑制剂耐药机制：一项系统综述
Cancers (Basel). 2020 Sep 29;12(10):2801. doi: 10.3390/cancers12102801.
10
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.河马通路转导蛋白YAP1/TEAD在HER2阳性乳腺癌中诱导对曲妥珠单抗的获得性耐药。
Cancers (Basel). 2020 Apr 29;12(5):1108. doi: 10.3390/cancers12051108.
本文引用的文献
1
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.河马效应器YAP可促进对RAF和MEK靶向癌症疗法的抗性。
Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.
2
The emerging roles of YAP and TAZ in cancer.YAP和TAZ在癌症中的新作用。
Nat Rev Cancer. 2015 Feb;15(2):73-79. doi: 10.1038/nrc3876. Epub 2015 Jan 16.
3
Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction.基于结构的强效环肽设计与合成，抑制YAP-TEAD蛋白-蛋白相互作用
ACS Med Chem Lett. 2014 Jul 14;5(9):993-8. doi: 10.1021/ml500160m. eCollection 2014 Sep 11.
4
Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research.可靠且有效的诊断是加速个性化癌症医学发展和变革癌症护理的关键：美国癌症研究协会的政策声明
Clin Cancer Res. 2014 Oct 1;20(19):4978-81. doi: 10.1158/1078-0432.CCR-14-2295. Epub 2014 Sep 9.
5
The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.Hippo 通路效应物 TAZ 和 YAP 在发育、稳态和疾病中的作用。
Development. 2014 Apr;141(8):1614-26. doi: 10.1242/dev.102376.
6
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.绘制人类肺癌中 BRAF 致癌基因依赖性的分子决定因素图谱。
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E748-57. doi: 10.1073/pnas.1320956111. Epub 2014 Feb 3.
7
Genetics and biomarkers in personalisation of lung cancer treatment.肺癌治疗个体化中的遗传学和生物标志物。
Lancet. 2013 Aug 24;382(9893):720-31. doi: 10.1016/S0140-6736(13)61715-8.
8
Circumventing cancer drug resistance in the era of personalized medicine.在个性化医疗时代规避癌症药物耐药性。
Cancer Discov. 2012 Mar;2(3):214-26. doi: 10.1158/2159-8290.CD-12-0012. Epub 2012 Feb 28.
9
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.RAF 抑制剂的临床疗效需要在 BRAF 突变型黑色素瘤中广泛的靶标阻断。
Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.
Zotero 插件